24/7 Patient Assistance: 760-405-8205

Kurt Tauer, MD

Medical Oncologist

Write a review
Doctor's profile photo

Request a call back

Conditions Treated Laryngeal Cancer Lung Cancer Ovarian Cancer Pericardial Mesothelioma Peritoneal Mesothelioma Pleural Mesothelioma Testicular Mesothelioma

  • Bio & Insurance Information
  • Education & Training

    dept_icon

    Saint Louis University

    Medical School

    dept_icon

    Baptist Memorial Hospital

    Residency

    dept_icon

    Memorial Sloan-Kettering Cancer Center

    Fellowship

  • Board Certifications

    American Board of Internal Medicine - Oncology

  • Hospital & Practice

    Baptist Memorial Hospital-Memphis

    Languages: English/Spanish

    (901) 226-5000

    6019 Walnut Grove Rd

    Memphis, Tennessee 38120

    Read More

    University of Tennessee Medical Center

    Languages: English/Spanish

    (865) 305-9000

    1924 Alcoa Hwy

    Knoxville, Tennessee 37920

    Read More
  • Publications & Memberships

    Dr. Kurt Tauer has contributed to 3 publications.

    Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumors.

    Stewart, C. F.,Tagen, M.,Schwartzberg, L. S.,Blakely, L. J.,Tauer, K. W.,Smiley, L. M.; Cancer Chemother. Pharmacol.. 2014 Jan 23.

    See more >>

    33 citations Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2-Negative Advanced Breast Cancer That Progressed during or after Bevacizumab.

    Schwartzberg, L. S.,Tauer, K. W.,Hermann, R. C.,Makari-Judson, G.,Isaacs, C.,Beck, J. T.,Kaklamani, V.,Stepanski, E. J.,Rugo, H. S.,Wang, W.,Bell-McGuinn, K.,Kirshner,...; Clin. Cancer Res.. 2013 May 15.

    See more >>

    Sorafenib (SOR) plus chemotherapy (CRx) for patients (pts) with advanced (adv) breast cancer (BC) previously treated with bevacizumab (BEV).

    Hudis C, Tauer KW, Hermann RC, Makari-Judson G, Isaacs C, Beck JT, Kaklamani VG, Stepanski EJ, Rugo HS, Wang W, Bell-McGuinn KM, Chera H, Zaugg B, Ro SK, Li S, Schwart...; J. Clin. Oncol.. 2011-05-20.

    See more >>